Novel Peptide Progresses to Phase 2 for the Treatment of Severe Burns
STONY BROOK, NY, February 5, 2025 (EINPresswire.com) – NeoMatrix Therapeutics, Inc., a clinical-stage company focused on developing a portfolio of novel, bioactive peptides announced that it received a grant from the US Department of Defense for a Phase 2a clinical trial for cP12. The cP12 Phase 2a study will be in 6 participants with burns up to 5% Total Body Surface Area and will be conducted at MedStar Washington Hospital Center.
NeoMatrix Therapeutics’ cP12 is a small peptide derived from the naturally occurring protein fibronectin, which has been shown to play an important role in many biological processes, including wound healing. In preclinical studies using a validated animal model, cP12 demonstrated an ability to limit burn injury progression, the cascade of events by which the tissue damage from the initial burn spreads into the deeper layers of the skin. The extent of progression after the initial burn determines the need for surgery and the extent of consequential scarring and disfigurement from serious burns. cP12’s optimum time of delivery is 2 to 8 hours.
“We see significant potential for NeoMatrix Therapeutics to continue to lead these programs through clinical investigations and identify new opportunities for the advancement of burn and other potential therapies” says Richard A. Clark, MD, company president and Chief Scientific Officer.
This effort is sponsored by the U.S. Government under Other Transactions Number W81XWH-15-9-0001, award HT9425-23-9-0022-004. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.
Safe Harbor:
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995 and are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties, many of which are outside of our control.
There can be no guarantees that our pipeline products will receive the necessary regulatory approvals or be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. These risks and uncertainties include, among others, our limited operating history, limited cash and a history of losses; our ability to obtain adequate financing to fund our operations; potential setbacks in our research and development efforts including negative or inconclusive results from our preclinical studies, our ability to secure required U.S. Food and Drug Administration or other approvals for our product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including on our operations and clinical trials; our ability to meet anticipated clinical trial commencement and completion dates and regulatory submission dates; negative or inconclusive results from our clinical trials or serious and unexpected drug-related side effects or other safety issues experienced by participants in our clinical trials; and delays; and changes in regulatory requirements, policy and guidelines. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Contact:
Richard A. Clark, M.D., President & Chief Scientific Officer raclark@neomatrixtx.com.